Immunic
IMUX
49 hedge funds and large institutions have $22.7M invested in Immunic in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 10 closing their positions.
123% more call options, than puts
Call options by funds: $874K | Put options by funds: $392K
0.77% less ownership
Funds ownership: 4.12% → 3.35% (-0.77%)
8% less funds holding
Funds holding: 53 → 49 (-4)
16% less capital invested
Capital invested by funds: $27M → $22.7M (-$4.3M)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$403K |
| 2 |
GC
Gratus Capital
Atlanta,
Georgia
|
+$312K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$125K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$66.4K |
| 5 |
SFP
Sweet Financial Partners
Fairmont,
Minnesota
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$1.69M |
| 2 |
Renaissance Technologies
New York
|
-$616K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$564K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$551K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$361K |
IMUX Hedge Fund Activity: Q4 2023 in Review
49 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2023, worth a combined $22.7M — down 16% from $27M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of IMUX and 7 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $403K. The largest seller was BVF Inc, exiting entirely with an estimated $1.69M sold.
- 49 institutional investors held Immunic (IMUX) as of Q4 2023, down from 53 in Q3 2023.
- Funds reported $22.7M of Immunic stock for Q4 2023, down 16% quarter-over-quarter.
- 7 funds opened new Immunic positions in Q4 2023 and 10 closed out, a net change of -3 holders.
- The largest Immunic buyer in Q4 2023 was Connective Capital Management, an estimated $403K added.
- The largest Immunic seller in Q4 2023 was BVF Inc, an estimated $1.69M sold.
Based on aggregated 13F filings for Q4 2023.